A Randomized, Double-Blind, Active-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F701 Solution in Female Subjects With Hair Loss
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs ENERGI-F701 (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Sponsors Energenesis Biomedical
- 02 Sep 2019 Planned End Date changed from 1 Mar 2019 to 3 Feb 2020.
- 02 Sep 2019 Planned primary completion date changed from 1 Dec 2018 to 3 Oct 2019.
- 31 May 2018 Status changed from not yet recruiting to recruiting.